

PARTICIPATING FACULTY

Anxiety Disorders in the 21st Century: Status, Challenges, Opportunities, and Comorbidity With Depression

This supplement to *The American Journal of Managed Care* includes information on how anxiety disorders will affect the 21st century. This program has been peer reviewed by experts in the field.

Faculty

Evelyn Chiao, PharmD

Outcomes Research Fellow
Applied Health Outcomes
Palm Harbor, Florida

C. Lindsay DeVane, PharmD

Professor of Psychiatry &
Behavioral Sciences
Medical University of
South Carolina
Charleston, South Carolina

Michael T. Eaddy, PharmD, PhD

Senior Consultant
Applied Health Outcomes
Palm Harbor, Florida

Meg Franklin, PharmD

Consultant
Applied Health Outcomes
Palm Harbor, Florida

Matthew S. Keene, MD

Executive Director
Scottsdale Center for the
Advancement of Neuroscience
Scottsdale, Arizona

Eric J. Kruep, PharmD, MS

Consultant
Applied Health Outcomes
Palm Harbor, Florida

Robert P. Mauch, Jr, PharmD, PhD

Director and Managing Partner
Applied Health Outcomes
Palm Harbor, Florida

Winnie W. Nelson, PharmD, MS

Consultant
Applied Health Outcomes
Palm Harbor, Florida

Patt Ellen Panzer, MD, MPH

Associate Medical Director
Blue Cross Blue Shield
of Delaware

Timothy S. Regan, BPharm, RPh, CPh

Associate Director
Applied Health Outcomes
Palm Harbor, Florida

Matthew W. Sarnes, PharmD

Senior Manager
Applied Health Outcomes
Palm Harbor, Florida

Manan B. Shah, PharmD, PhD

Consultant
Applied Health Outcomes
Palm Harbor, Florida

David V. Sheehan, MD, MBA

Professor of Psychiatry
Director of Psychiatric Research
University of South Florida
College of Medicine
Tampa, Florida

Faculty Disclosure

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

■ **C. Lindsay DeVane, PharmD**

Consultant to:

Bristol-Myers Squibb
GlaxoSmithKline
Janssen
Novadel

Grant support from:

Cyberonics
Janssen

■ **Matthew S. Keene, MD**

Advisor to:

Cephalon
Forrest
GlaxoSmithKline
Pfizer

■ **David V. Sheehan, MD, MBA**

Consultant/advisor to:

AstraZeneca
Avera
GlaxoSmithKline
Janssen
Jazz Pharmaceuticals
MediciNova
Pfizer
Solvay

Grant/research support from:

GlaxoSmithKline
Janssen
Jazz Pharmaceuticals
MediciNova
Pfizer

This participant reported no financial affiliations.

■ **Patt Ellen Panzer, MD, MPH**

GlaxoSmithKline provided funding to Applied Health Outcomes to perform research and development related to this manuscript. The following authors are employed by Applied Health Outcomes.

■ **Evelyn Chiao, PharmD**

■ **Michael T. Eaddy, PharmD, PhD**

■ **Meg Franklin, PharmD**

■ **Eric J. Kruep, PharmD, MS**

■ **Robert P. Mauch, Jr, PharmD, PhD**

■ **Winnie W. Nelson, PharmD, MS**

■ **Timothy S. Regan, BPharm, RPh, CPh**

■ **Matthew W. Sarnes, PharmD**

■ **Manan B. Shah, PharmD, PhD**

The following authors received an honorarium from Applied Health Outcomes, which receives grant support from GlaxoSmithKline and other pharmaceutical companies.

■ **C. Lindsay DeVane, PharmD**

■ **Matthew S. Keene, MD**

■ **Patt Ellen Panzer, MD, MPH**

■ **David V. Sheehan, MD, MBA**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

*Anxiety Disorders in the 21st Century:
Status, Challenges, Opportunities, and
Comorbidity With Depression*

This supplement has been supported by funding from **GlaxoSmithKline**.

• • •

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.